ischemic heart disease
Conditions
Interventions
36weeks 10 mg/day of rosuvastatin 1800 mg/day of eicosapentaenoic acid
36weeks 5 mg/day of rosuvastatin 1800 mg/day of eicosapentaenoic acid
36weeks 5 mg/day of rosuvastatin
Sponsors
Kobe University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 over 20 years 2 Patients implanted EES neoatherosccrelosis with NA by OCT 3 LDL is or less than 100 mg/dl after ingesting 5 mg/day of rosuvastatin
Exclusion criteria
Exclusion criteria: 1 Patients taking omega 3 fatty acid before randomization 2 Patients allergic to rosuvastatin or eicosapentaenoic acid 3 Patients with a history of hemorrhagic stroke 4 Patients taking anti cancer agent 5 Patients undergoing LDL apheresis 6 Patients with severe liver disease or severe kidney disease 7 Patients who conflict with any of the warnings or contraindications listed in the domestic package insert of rosuvastatin 8 Patients who conflict with any of the warnings or contraindications listed in the domestic package insert of eicosapentaenoic acid 9 Patients perfomed PCI with restenosis of target lesion 10 Pregnant women or patients with possibilty of Pregnancy or nursing woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lipid index | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Major adverse cardiac event 2 follow up OCT data Minimum lumen area, average neointimal thickness, lipid arc, lipid length, TCFA, macrophage grade 3 NIRS IVUS LCBI 4mm, plaque volume | — |
Countries
Japan
Contacts
Public ContactShinsuke Nakano
Kobe University Hospital Cardiology
Outcome results
None listed